Jyong Biotech Ltd. (MENS)
Jyong Biotech will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$7.50 - $8.50
Shares Offered
2,666,667
Deal Size
$21.33M

Company Description

Jyong Biotech is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China).

Among our drug candidates, we have filed the new drug application in the US, for MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms.

PCP, our key new drug candidate developed for the prevention of prostate cancer, is under phase II trials stage in Taiwan.

Another preclinical-stage key drug candidate, IC, is under preclinical studies for the treatment of interstitial cystitis.

Jyong Biotech Ltd.
CountryTaiwan
Founded2002
IndustryBiotechnology
SectorHealthcare
Employees31
CEOFu-Feng Kuo

Contact Details

Address:
23F-3, No. 95, Section 1, Xintai 5th Road
Xizhi District, New Taipei City 221
Taiwan
Phone+886-2-2732-5205
Websitehealtheverbiotech.com

Stock Details

Ticker SymbolMENS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001954488
SIC Code2834

Key Executives

NamePosition
Fu-Feng KuoChairwoman of the Board of Directors and Chief Executive Officer
Fenglin HsuDirector Nominee and Chief Technology Officer Nominee
Hung-Shu FanIndependent Director Nominee
Pang-Chief ChiIndependent Director Nominee
Ming Tsan HsuIndependent Director Nominee
Alfred YingChief Financial Officer Nominee
Wanwen (Angela) SuChief Science Officer Nominee

Latest SEC Filings

DateTypeTitle
Jun 30, 2025SP 15D2Filing
Jun 20, 20256-KReport of foreign issuer
Jun 18, 2025424B4Prospectus
Jun 16, 2025EFFECTNotice of Effectiveness
Jun 16, 2025CERTCertification by an exchange approving securities for listing
Jun 12, 20258-A12BRegistration of securities
Jun 6, 2025POS AMPost-Effective amendments for registration statement
Apr 23, 2025POS AMPost-Effective amendments for registration statement
Mar 31, 2025EFFECTNotice of Effectiveness
Mar 27, 2025FWPFree Writing Prospectus